Innovus Pharmaceuticals says that it has ordered 220,000 units of FlutiCare, an OTC fluticasone propionate nasal spray, in preparation for its US launch in the fourth quarter of 2017. The company says that it will launch a 120 spray version of the product for the treatment of allergic rhinitis.
Innovus acquired the FlutiCare brand in 2015 when it acquired Novalere FP; however, a delay in review of the ANDA for the Novalere product led the company to acquire US rights to a fluticasone nasal spray from West-Ward earlier this year to market under the FlutiCare name.
According to Innovus, it has ordered a single batch of Fluticare from West-Ward for 2017 and has committed to purchasing additional batches through 2019.
Read the Innovus press release.
